Aptamer Group plc, renowned for pioneering Optimer® binders that drive innovation in the life sciences sector, has formalized a substantial agreement with a biotechnology company specializing in genetic medicines.
In accordance with the agreement's terms, Aptamer Group will leverage its cutting-edge platform to discover Optimer binders, facilitating the precise targeting of genetic medicines toward specific cell types. In recognition of its efforts, Aptamer Group stands to receive development fees totaling up to £553,000 for the discovery and development of these Optimer binders. The initiation of work is imminent, contingent upon the receipt of target materials from the client, and the anticipated completion is within the current financial year.
Optimer binders represent a groundbreaking category of molecules designed for the selective targeting of emerging biomarkers and tissues. These fully synthetic oligonucleotide molecules, known as Optimers, undergo a controlled development process, resulting in high-affinity and highly selective binders. Their appeal as potential molecules for drug delivery lies in their smaller size, enhancing tissue penetration for effective therapeutic delivery. Additionally, the ability to precisely control the conjugation of Optimers to therapeutic payloads ensures precision in therapeutic development and dosing.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!